Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation

Matsumoto, Yoshiko; Yoshida, Yoichiro; Kiba, Sachiko; Yamashiro, Shizuka; Nogami, Haruka; Ohashi, Nobuyuki; Kajitani, Ryuji; Munechika, Taro; Nagano, Hideki; Komono, Akira; Aisu, Naoya; Yoshimatsu, Gumpei; Hasegawa, Suguru

doi:10.1007/s00520-020-05387-z

Cited by 8 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6.7%). 9 Accordingly, the preventive effect of EA may not be strong enough to alleviate pain and tingling in the hands. Patients' physical status, ADLs and social lives appeared to be improved, as physical function, role function and social function scores, respectively, were higher in the EA group than the SA group at some time points during chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…3 A cohort study showed that the average duration from oxaliplatin administration to CIPN symptom development was 182 min (range = 62-443 min). 9 Moreover, there was a significant association between acute CIPN and chronic CIPN. 10 The most common location of acute CIPN was the fingers, in which light touch sensation worsened significantly even after one cycle of chemotherapy.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial

Chan

Lui²,

Lam³

et al. 2022

Acupunct Med

View full text Add to dashboard Cite

Background: Oxaliplatin-based chemotherapy is a major first-line conventional therapy for advanced and metastatic colorectal cancer (CRC). However, oxaliplatin causes chemotherapy-induced peripheral neuropathy (CIPN). Acupuncture has long been used to alleviate limb numbness in Chinese medicine practice. Aim: The aim of this study was to examine the efficacy and safety of electroacupuncture (EA) for the alleviation of CIPN in CRC patients. Design: This was a pilot single-blinded, randomized, sham-controlled trial. Setting/participants: Sixty eligible patients, who had been diagnosed with CRC and were undergoing oxaliplatin-based chemotherapy, were randomized in a ratio of 1:1 to the EA intervention group or sham acupuncture (SA) control group. During a 12-week treatment period, patients in the EA group received EA once a week, while patients in the SA group received SA; both groups were followed up for 12 weeks. Results: Compared with the SA group, the EA group exhibited significant alleviation of CIPN severity during chemotherapy. Moreover, EA also improved the physical function, role function, and social function of CRC patients. However, there were no significant differences in tests of vibration or light touch sensation. In addition, EA appeared to be a safe treatment for CIPN and was both feasible and acceptable to CRC patients during chemotherapy. Conclusion: This study showed preliminary evidence for the efficacy and safety of EA in acute CIPN among CRC patients, although further studies are needed to verify these effects and to further explore the potential role of EA in chronic CIPN (effects on which remain unclear). Trial registration number: NCT03582423 (ClinicalTrials.gov)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial

Chan

Lui²,

Lam³

et al. 2022

Acupunct Med

View full text Add to dashboard Cite

show abstract

“…Diverse strategies have been employed for assessing acute OXA neurotoxicity. The Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI.CTC) [ 10 , 44 , 50 ], the oxaliplatin-specific neurotoxicity scale [ 51 ], or a score based on recording the frequency of symptoms with an OXA-Neuropathy Questionnaire (yes/no response format) [ 17 , 52 , 53 ], are among the most common systems for recording their presence in the daily practice. The severity of acute neurotoxicity syndrome has been defined according the burden of symptoms [ 54 ], or according to a visual analogical scale 0 (no problem) to 10 (major problem) numerical rating scale for any of the four acute neuropathy symptoms [ 48 , 55 , 56 ].…”

Section: Clinical Factors Associated With Oxaipnmentioning

confidence: 99%

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Velasco

Alemany

Villagrán

et al. 2021

JPM

View full text Add to dashboard Cite

Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.

show abstract

“…4 Neuropathy occurs in almost 90% of patients within hours of infusion, and is characterized by dysesthesia and paresthesia of the hand, feet and numbness in the extremities, resulting in sensory ataxia and functional impairment. 5 It occurs after six cycles of treatment in 10-15% of all patients, while it occurs after completing chemotherapy with oxaliplatin in 80% of cases. 4 Oxaliplatin is commonly used in the treatment of colorectal cancer, in either the adjuvant or palliative therapy, and indicated in the treatment of gastroesophageal cancer and pancreatic cancer.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients

Mahmoud

Said

Berguiga

et al. 2021

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Oxaliplatin utilized in colorectal neoplasms treatment could induce acute peripheral neuropathy (APN) which is a dreadful and frequent adverse event. The objective of this study is to estimate incidence of APN induced by oxaliplatin cumulative incidence in cancer patients colorectal and to describe the distribution of the APN incidence according to demographic and clinical characteristics, as well as according to oxaliplatin cumulative dose. Material and methods This is a prospective descriptive study which took place from June to December 2018 at the Salah Azaiz Institute, Tunis. Demographic data, clinical data and data on oxaliplatin administration were collected from patient interview, medical files and pharmaceutical databases. Results The APN (grade 1, grade 2 and grade 3) cumulative incidence during the period of six months of follow up was 86% (95% CI [0.7815–0.9132]). While 38.3% (95% CI [0.29–0.48]) of the patients had grade 2 or 3 neuropathy. The search for factors associated with the risk of grade 2 and 3 NAP revealed trend significant association with diabetes (adjusted RR = 5.7 (IC95% [0.9- 37.3]; p = 0.07). Moreover, there was significant association with oxaliplatin cumulative dose (≥421 mg/m2) to increase the risk of APN grade 2 and 3 (adjusted RR = 7.8; [2.7–22.7]; p = 0.0001). Furthermore, significant association with obesity to increase the risk of APN grade 2 and 3 (adjusted RR = 5.3 [1.1- 25.4]; p = 0.04) was found. Among the patients included, 31.1% experienced oxaliplatin dose reduction and in the majority of cases this reduction is due to neurotoxicity (90.9%). Conclusion The high incidence of oxaliplatin-induced APN remains an embarrassing and handicapping side effect. Our study has shown that oxaliplatin cumulative dose (≥421 mg/m2), diabetes and obesity are risk factor for the development of grade 2 and 3 APN.

show abstract

Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation

Cited by 8 publications

References 28 publications

Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial

Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients

Contact Info

Product

Resources

About